CareDx (CDNA) Stock Price, News & Analysis

Company Overview

CareDx, Inc. is a healthcare diagnostics company focused on improving the care of organ-transplant patients. The company develops and commercializes noninvasive tests and digital tools intended to help physicians assess transplant-organ health, identify potential rejection, and support long-term patient management.

Its offerings include AlloSure donor-derived cell-free DNA tests for monitoring transplant recipients, AlloMap gene-expression testing for heart-transplant patients, and HeartCare, which combines AlloMap and AlloSure results. CareDx also provides transplant-monitoring solutions such as TruGraf kidney-transplant testing, patient engagement services, and clinical decision-support tools designed to complement traditional biopsies and other laboratory assessments.

Founded in 1998 and headquartered in Brisbane, California, CareDx serves transplant centers, physicians, and patients primarily in the United States, with its products and services also supporting transplant care internationally. The company became publicly traded on the Nasdaq exchange in 2014 under the symbol CDNA.

Key Stats

• Today's Range: $65.89 to $70.81
• 50-Day Range: $45.32 to $69.85
• 52-Week Range: $14.03 to $72.51
• Volume: 1.56 million shs
• Average Volume: 1.58 million shs
• Market Capitalization: $3.58 billion
• P/E Ratio: 394.59
• Dividend Yield: N/A
• Price Target: $57.00
• Consensus Rating: Hold

CareDx Stock Analysis - MarketRank™

CareDx scored higher than 34% of companies evaluated by MarketBeat, and ranked 723rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

CareDx has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 3 buy ratings, 5 hold ratings, and no sell ratings.

Downside Risk

CareDx has a consensus price target of $57.00, representing about 17.6% downside from its current price of $69.20.

Amount of Analyst Coverage

CareDx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 34.04%

Earnings Growth

Earnings for CareDx are expected to grow by 34.04% in the coming year, from $0.47 to $0.63 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CareDx is 394.59, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of CareDx is 394.59, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 192.40.

Price to Book Value per Share Ratio

CareDx has a P/B Ratio of 11.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.05% of the float of CareDx has been sold short.

Short Interest Ratio / Days to Cover

CareDx has a short interest ratio ("days to cover") of 4.56.

Change versus previous month

Short interest in CareDx has recently increased by 4.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CareDx does not currently pay a dividend.

Dividend Growth

CareDx does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

CareDx has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for CareDx this week, compared to 4 articles on an average week.

Search Interest

Only 7 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,676,640.00 in company stock.

Percentage Held by Insiders

2.40% of the stock of CareDx is held by insiders.

Percentage Held by Institutions

CareDx has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/20/2026
• Next Earnings (Confirmed): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CDNA
• CIK: 1217234
• Web: www.caredx.com
• Phone: (415) 287-2300
• Fax: 415-287-2450
• Employees: 765
• Year Founded: 2000

Price Target and Rating

• Average Price Target for CareDx: $57.00
• High Price Target: $80.00
• Low Price Target: $21.00
• Potential Upside/Downside: -17.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.07
• Trailing P/E Ratio: 394.59
• Forward P/E Ratio: 147.23
• P/E Growth: N/A
• Net Income: -$21.35 million
• Net Margins: 24.23%
• Pretax Margin: 25.15%
• Return on Equity: 2.87%
• Return on Assets: 2.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.58
• Quick Ratio: 4.51

Sales & Book Value

• Annual Sales: $379.80 million
• Price / Sales: 9.43
• Cash Flow: $0.01 per share
• Price / Cash Flow: 10,298.77
• Book Value: $5.89 per share
• Price / Book: 11.75

Miscellaneous

• Outstanding Shares: 51,730,000
• Free Float: 50,492,000
• Market Cap: $3.58 billion
• Optionable: Optionable
• Beta: 2.38